NVIDIA now produces more free cash flow than Microsoft. https://t.co/f1BzrTALze ...

Core Insights - Artificial intelligence (AI) is a significant driver for large-cap ETFs focused on growth, with companies like Broadcom, Palantir, and Nvidia being essential for AI infrastructure [1][2] - The global AI infrastructure market is projected to reach $356 billion by 2032, with big tech expected to invest $155 billion in AI development by 2025, indicating substantial growth potential [2] Company Summaries - **Broadcom**: Holds a 3.52% allocation in the VictoryShares Free Cash Flow Growth ETF (GFLW). It designs semiconductors and networking solutions crucial for AI data flow and connectivity, widely used in data centers and communications networks [3][10] - **Nvidia**: Allocated 4.04% in GFLW. It develops GPUs and platforms that are foundational for AI workloads, utilized globally by enterprises and governments for training and deploying AI models [4][10] - **Palantir**: With a 2.56% allocation in GFLW, it focuses on software platforms that assist organizations in managing data and applying AI for operational decision-making, serving both public and private sectors [5][6][10] Financial Performance - All three companies—Broadcom, Nvidia, and Palantir—exhibit consistent cash generation and disciplined capital management, emphasizing financial flexibility through effective free cash flow utilization [7][10] - GFLW tracks the Victory Free Cash Flow Growth Index, which targets large-cap companies with the potential for future free cash flow generation, rather than solely relying on past performance [9][10]

Oct 28, 2025 6:45 AM Eastern Daylight Time Tenet Reports Strong Third Quarter 2025 Results; Raises 2025 Financial Outlook Share DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for the quarter ended September 30, 2025. "Our high acuity service line focus and operational discipline enabled us to deliver strong same store revenue growth and attractive operational performance and free cash flow in the third quarter," said Saum Sutaria, M.D., Chairman and Chi ...

Core Insights - Applied Industrial Technologies reported a net sales increase of 9.2% year-over-year for the first quarter of fiscal 2026, reaching $1.2 billion, with organic sales growth of 3.0% [2][7] - The company achieved a net income of $100.8 million, or $2.63 per diluted share, reflecting an 11.4% increase compared to the previous year [2][7] - EBITDA for the quarter was reported at $146.3 million, marking a 13.4% year-over-year growth [2][7] Financial Performance - Net sales for the quarter were $1.2 billion, up 9.2% from $1.1 billion in the prior year [2][9] - Organic sales growth was 3.0%, driven by a 4.4% increase in the Service Center segment, while the Engineered Solutions segment saw a slight decline of 0.4% [2][3] - The company reported an EBITDA margin of 12.2%, an increase of nearly 50 basis points from the prior year [3] Guidance and Outlook - The company has modestly increased its fiscal 2026 EPS guidance to a range of $10.10 to $10.85, up from the previous range of $10.00 to $10.75 [3][7] - Sales guidance remains at an increase of 4% to 7%, with organic growth expected to be between 1% to 4% [3] - The company anticipates gradual improvement in end-market demand, despite ongoing macroeconomic uncertainties and inflationary pressures [3] Dividend Announcement - The Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable on November 28, 2025 [4]

Core Insights - The Inspire 500 ETF (NYSEARCA: PTL) is a passively managed fund focusing on the 500 most generously valued U.S. companies [1] - The fund's strategy is informed by the research of individual investor Vasily Zyryanov, who emphasizes the importance of Free Cash Flow and Return on Capital in investment analysis [1] - Zyryanov's research spans various sectors, particularly the energy sector, while also covering industries such as mining, chemicals, and luxury goods [1] Investment Strategy - The ETF targets both underpriced equities with strong upside potential and overappreciated companies with inflated valuations [1] - A meticulous approach is advocated, where investors should assess deeper financial metrics beyond simple profit and sales analysis [1] - The analysis acknowledges that some growth stocks may justify their premium valuations, highlighting the need for thorough investigation into market perceptions [1]

the busiest week of earning season is upon us. We want to bring in Stephanie Link for this stuff. It's not just earning season, man.We've we've got this potential trade deal that looks like it's a much better situation. We are have the markets at new highs. We've got the futures up sharply this morning.Kind of on a roll here. Does that make you feel good or do you get nervous when things are this good. >> Oh, I feel really good, Becky, and thanks for having me.Good morning. Uh the economy is hanging in ther ...

Financial Performance & Capital Allocation - Diamondback generated $1,242 million in Free Cash Flow ("FCF") in Q2 2025, which translates to $425 per share[17] - Adjusted FCF for Q2 2025 was $1,334 million, or $457 per share, excluding $40 million of merger and transaction expenses and $52 million of early derivative termination payments[17] - The company expects to generate at least $58 billion of Adjusted FCF in 2025 at current commodity prices[17] - Approximately 52% of Q2 2025 Adjusted FCF was returned to stockholders, totaling $691 million, through base dividends and share repurchases[15, 17] - The share repurchase authorization was increased by $20 billion, bringing the total to $80 billion, with approximately $35 billion remaining[17] Operational Highlights & Asset Overview - Diamondback's market capitalization is $42,306 million, with net debt of $15,098 million, resulting in an enterprise value of $61,342 million[16] - The company has significant scale with approximately 859,000 net acres and run-rate production of approximately 490 Mbo/d (~905 Mboe/d) beginning in Q3[19] - Diamondback possesses best-in-class inventory depth and quality, with approximately 9,600 gross Permian Basin locations economic at $50 / Bbl[20] - The company's unhedged realized cash margin was 73% in Q2 2025[24] Updated Guidance - The company anticipates full year 2025 oil production to be between 485 and 492 Mbo/d (890 – 910 Mboe/d)[69, 71] - The full year 2025 CAPEX budget is projected to be between $34 and $36 billion[69, 71]

Core Insights - Equity investors are concerned about the market rally's lack of breadth, indicating that a small number of companies are driving the market's performance [1] Group 1: Investment Strategies - The individual investor and writer, Vasily Zyryanov, focuses on identifying underpriced equities with strong upside potential and overappreciated companies with inflated valuations [1] - Zyryanov emphasizes the importance of analyzing Free Cash Flow and Return on Capital in addition to profit and sales to gain deeper insights into investments [1] - While favoring underappreciated equities, Zyryanov acknowledges that some growth stocks may warrant their premium valuations, highlighting the need for thorough analysis to determine market correctness [1] Group 2: Sector Focus - Zyryanov pays particular attention to the energy sector, including oil & gas supermajors, mid-cap, and small-cap exploration & production companies, as well as oilfield services firms [1] - His research also encompasses various other industries, such as mining, chemicals, and luxury goods [1]

Core Insights - The company is optimistic about its future, focusing on improving healthcare experiences and operational performance while maintaining financial discipline [4][29][30] Financial Performance - The third quarter results showed a 6% year-over-year increase in same store net revenue, driven by a 5.6% rise in net revenue per adjusted admission [5][10] - Adjusted EBITDA for the third quarter was $376 million, up from $347 million in the prior year, with a margin increase of 100 basis points to 12.2% [9][10] - The company recognized a $28 million gain from a legal settlement, which contributed to the reported results [5][10] Operational Highlights - Inpatient volume growth continued, although the business mix remains skewed towards medical cases rather than surgical ones [6][11] - The company is expanding its service lines, including new urology and neurosurgery programs, and has successfully recruited approximately 160 more employed physicians and advanced practice providers [7][8] - The capital structure improved, with leverage reduced to 6.7 times from 7.4 times at year-end 2024 [8][15] Strategic Initiatives - A leadership conference is planned for 150 CEOs and CFOs to discuss the company's vision and commitment to quality investments [4] - The company is pursuing divestitures and has ongoing discussions for potential deals, indicating a strategic approach to capital deployment [22][25] Market Trends - There is a noted improvement in payer mix, which is expected to positively impact future volumes as consumer confidence stabilizes [20][36] - The company is observing a slight recovery in outpatient elective surgeries, although overall outpatient volumes remain under pressure [19][20] Future Outlook - The adjusted EBITDA guidance for the full year 2025 has been tightened to a range of $1.5 to $1.55 billion, reflecting the impact of the legal settlement and operational performance [16] - Anticipated Medicare rate increases and potential new state-directed payment programs are expected to provide incremental benefits in 2026 [25][40]

Financial Data and Key Metrics Changes - Community Health Systems reported a 6% year-over-year increase in net revenue for Q3 2025, driven by improvements in payer mix and state-directed payments from New Mexico and Tennessee [7][12] - Adjusted EBITDA for Q3 2025 was $376 million, up from $347 million in the prior year, with a margin of 12.2%, reflecting a 100 basis point increase year-over-year [11][12] - The company reduced its leverage to 6.7 times, down from 7.4 times at year-end 2024, following the refinancing of $1.74 billion of senior secured notes [9][16] Business Line Data and Key Metrics Changes - Same-store net revenue increased by 6.0% year-over-year, with net revenue per adjusted admission rising by 5.6% [12][63] - Same-store inpatient admissions grew by 1.3% year-over-year, while same-store surgeries declined by 2.2% [12] - The company successfully recruited approximately 160 more employed physicians and advanced practice providers compared to the previous year [9] Market Data and Key Metrics Changes - The company experienced a divergence in inpatient and outpatient surgeries, with outpatient surgeries down due to economic headwinds affecting consumer demand [12][20] - Improvement in payer mix was noted, particularly in commercially insured business, contributing to the overall positive trends in Q3 [21][47] Company Strategy and Development Direction - The company is focused on investments in quality care, improving physician and patient experiences, and achieving sustainable positive free cash flow [6][7] - Plans for 2026 include continued growth investments and potential divestitures, with a focus on expanding access points such as ambulatory surgery centers and freestanding emergency departments [59][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing improvements in consumer confidence and payer mix as positive indicators for recovery in outpatient volumes [20][21] - The company anticipates a strong Medicare rate increase for 2026, which could positively impact financial performance [30] Other Important Information - The company expects to close the divestiture of its outreach lab assets later this quarter, with proceeds of approximately $195 million [17] - Cash flows from operations for Q3 were reported at $70 million, with adjusted cash flows from operations for the year to date at $403 million [15][16] Q&A Session Summary Question: Thoughts on outpatient volume recovery - Management noted that economic headwinds and consumer confidence have impacted outpatient surgeries, but improvements in payer mix provide some optimism for recovery [20][21] Question: Divestiture plans for 2026 - Management confirmed ongoing discussions for potential divestitures, with some advanced discussions expected to yield announcements later this year [24] Question: Free cash flow outlook for 2025 - Management indicated confidence in achieving positive free cash flow for the full year 2025, which would allow for strategic capital deployment [27][28] Question: Trends in payer denials and underpayments - Management reported stabilization in denials since a spike in the previous year, with ongoing investments in revenue cycle management to mitigate pressures [68] Question: Impact of flu season on guidance - Management acknowledged that flu season has started slowly, but this has been factored into their guidance [71]